Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 7-12

  Boudny, Vladimir ^a,b   Nakano, Shuji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Apoptosis; c H ras; Taxol; Taxotere; v Src

Indexed keywords

DOCETAXEL; PACLITAXEL; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL DEATH; ENZYME ACTIVATION; EPITHELIUM CELL; GALLBLADDER EPITHELIUM; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZOQUINONES; GALLBLADDER NEOPLASMS; GENES, RAS; GENES, SRC; HUMANS; LACTAMS, MACROCYCLIC; ONCOGENE PROTEIN PP60(V-SRC); PACLITAXEL; PROTEIN KINASE C; QUINONES; RAS PROTEINS; TAXOIDS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037234153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
2. Manfredi JJ and Horwitz SB: Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83-125, 1984.
3. Ringel I and Horwitz SB: Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
4. Bissery MC, Guenard D, Gueritte-Voegelein F and Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991.
5. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
6. Haldar S, Jena N and Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
7. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
8. Haldar S, Basu A and Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997.
9. Hennipman A, van Oirschot BA, Smits J, Rijksen G and Staal GEJ: Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res 49: 516-521, 1989.
10. Ottenhoff-Kalff AE, Rijksen G, van Beurden EACM, Hennipman A, Michels AA and Staal GEJ: Characterization of protein tyrosine kinases from human breast cancer: involvement of c-src oncogene product. Cancer Res 52: 4773-4778, 1992.
11. Bolen JB, Veillette A, Schwartz AM, DeSeau V and Rosen N: Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 84: 2251-2255, 1987.
12. c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 87: 558-562, 1990.
13. c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60, 1993.
14. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R and Yeatman TJ: Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15: 3083-3090, 1997.
15. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R and Yetman TJ: Activating Src mutation in a subset of advanced human colon cancers. Nature Genet 21: 187-190, 1999.
16. Brown MT and Cooper JA: Regulation, substrates and functions of src. Biochim Biophys Acta 1287: 121-149, 1996.
17. Avruch J, Zhang XF and Kyriakis JM: Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 19: 279-283, 1994.
18. Wang LG, Liu XM, Kreis W and Budman DR: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44: 355-361, 1999.
19. Blagosklonny MV, Schulte TW, Nguyen P, Trepel J and Neckers LM: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851-1854, 1996.
20. Blagosklonny MV, Giannakakou P, El-Deity WS, Kingston DJI, Higgs PI, Neckers LM and Fojo T: Raf-1/Bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57: 130-135, 1997.
21. Blagosklonny MV, Chuman Y, Bergan RC and Fojo T: Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 13: 1028-1036, 1999.
22. Nakano S, Tatsumoto T, Esaki T, Nakamura M, Baba E, Kimura A, Ohshima K and Niho Y: Characterization of a newly established human gallbladder-carcinoma cell line. In Vitro Cell Dev Biol Anim 30A: 729-732, 1994.
23. Tatsumoto T, Nakano S, Shimizu K, Ono M, Esaki T, Ohshima K and Niho Y: Direct tumorigenic conversion of human gallbladder-carcinoma cells by v-src but not by activated c-H-ras oncogene. Int J Cancer 61: 206-213, 1995.
24. Kusumoto M, Ogawa T, Mizumoto K, Ueno H, Niiyama H, Sato N, Nakamura M and Tanaka M: Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effect on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clinical Cancer Res 5: 2140-2147, 1999.
25. Hidaka H, Inagaki M, Kawamoto S and Sasaki Y: Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23: 5036-5041, 1984.
26. Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, Fukui Y, Nonomura Y and Matsuda Y: Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol-3 kinase in RBL-2H3 cells. J Biol Chem 268: 25846-25856, 1993.
27. Ibrado AM, Liu L and Bhalla K: Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 57: 1109-1115, 1997.
28. Ling YH, Tornos C and Perez-Soler R: Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 273: 18984-18991, 1998.
29. Srivastava RK, Mi Q-S, Hardwick M, and Longo DL: Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96: 3775-3780, 1999.
30. Boudny V and Nakano S: Src tyrosine kinase but not activated ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells. Brit J Cancer 86: 463-469, 2002.
31. Wang H-G, Miyashita T, Takayama S, Sato T, Torigoe S, Krajewski S, Tanaka S, Hovey L, Troppmair J, Rapp UR and Reed JC: Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 9: 2751-2756, 1994.
32. Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R and Pratt WB: Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 268: 21711-21716, 1993.
33. Wartmann M and Davis RJ: The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J Biol Chem 269: 6695-6701, 1994.
34. Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91: 8324-8328, 1994.